Literature DB >> 31207250

Management of two cavernous sinus dural arteriovenous fistulae by direct microsurgical approach and catheterization of the superior ophthalmic vein.

N Serratrice1, G Baucher2, A Reyre3, H Brunel4, S Fuentes5, H Dufour6.   

Abstract

BACKGROUND: In case of cavernous sinus dural arteriovenous fistula, transvenous embolization of the cavernous sinus via the inferior petrosal sinus is generally sufficient. However, when inferior petrosal sinus access is challenging, various alternative approaches have been reported, with corresponding difficulties and risks. CASE REPORTS: We report the management of two cases of life-threatening cavernous sinus dural arteriovenous fistula revealed by a typical cavernous sinus syndrome. Conventional approaches were unsuccessful, and a direct microsurgical approach was performed, with catheterization of the superior ophthalmic vein. This combined approach safely accessed the cavernous sinus, and obtained complete occlusion of the fistulae by Onyx® embolization.
CONCLUSIONS: This procedure could be an interesting alternative option in the treatment of cavernous sinus dural arteriovenous fistula when conventional approaches are not possible.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cavernous sinus dural arteriovenous fistula; Interventional neuroradiology; Neurosurgery; Ophthalmic vein

Mesh:

Substances:

Year:  2019        PMID: 31207250     DOI: 10.1016/j.neuchi.2019.05.005

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  2 in total

1.  Percutaneous Ultrasound-Guided Access to the Superior Ophthalmic Vein for Embolization of a Cavernous Sinus Dural Arteriovenous Fistula.

Authors:  Pham Hong Duc; Nguyen Thi Thai Hoa; Huynh Quang Huy; Anh Quoc Nguyen
Journal:  Cureus       Date:  2020-05-11

Review 2.  Endovascular treatment of the cavernous sinus dural arteriovenous fistula: current status and considerations.

Authors:  Kun Hou; Guichen Li; Tengfei Luan; Kan Xu; Jinlu Yu
Journal:  Int J Med Sci       Date:  2020-05-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.